ERBB2 and breast carcinoma: Our laboratory showed that silencing E2F3 in HCC1954 Her2+ breast cancer cells resulted in a significant delay in the completion of cytokinesis [62] and that tumor suppression triggered by silencing E2F3 in breast cancer cells is strongly associated with significant reductions in percentages of mitotic cells [63].